dr. zhu on primary resistance to osimertinib in egfr-mutant nsclc
Published 5 years ago • 312 plays • Length 2:23Download video MP4
Download video MP3
Similar videos
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
1:33
dr. yang on resistance mechanisms from osimertinib in nsclc
-
1:43
dr. padda on overcoming resistance to osimertinib in egfr nsclc
-
5:52
treatment of egfr nsclc after osimertinib
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
-
5:46
resistance mechanisms in egfr nsclc
-
1:16
dr. goldberg on options after developing resistance to osimertinib for nsclc
-
0:42
can we predict osimertinib resistance?
-
2:20
dr. liu on resistance mechanisms in egfr-mutant lung cancer
-
5:52
mechanisms of osimertinib resistance in aura 3
-
0:55
dr. reimuth discusses studies looking at resistance to egfr tkis in nsclc
-
4:32
resistance mechanisms in egfr-positive nsclc
-
6:06
osimertinib, the standard for egfr nsclc
-
1:40
dr. kris on predicting benefit with osimertinib in egfr nsclc
-
1:31
dr. oxnard on detecting resistance mechanisms after treatment with osimertinib
-
1:37
dr. konduri on treatment options for patients with egfr-mutant nsclc
-
1:58
dr. bazhenova on sequencing beyond progression in egfr-mutant nsclc
-
2:14
dr. yang on osimertinib as first-line therapy for egfr-positive nsclc